---
title: "RPC: Moxifloxacin Hydrochloride Eye Drops have obtained a drug registration certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/231180339.md"
description: "RPC announced that its subsidiary Jiangxi Shining Pharmaceutical Co., Ltd. has obtained the Drug Registration Certificate for Moxifloxacin Hydrochloride Eye Drops issued by the National Medical Products Administration. This medication is used to treat bacterial conjunctivitis caused by sensitive microorganisms and has been included in the Category B drug list of the medical insurance catalog, marking its successful completion of the consistency evaluation for generic drugs"
datetime: "2025-03-10T08:20:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/231180339.md)
  - [en](https://longbridge.com/en/news/231180339.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/231180339.md)
generator: "portal-rs"
---

# RPC: Moxifloxacin Hydrochloride Eye Drops have obtained a drug registration certificate

According to the Zhitong Finance APP, RPC (000650.SZ) announced that its subsidiary Jiangxi Shining Pharmaceutical Co., Ltd. recently received the drug registration certificate for Moxifloxacin Hydrochloride Eye Drops approved and issued by the National Medical Products Administration.

Moxifloxacin Hydrochloride Eye Drops are clinically used for the treatment of bacterial conjunctivitis caused by sensitive microorganisms (including: Gram-positive bacteria, Gram-negative bacteria, Chlamydia trachomatis, etc.) and are classified as Category B drugs in the medical insurance catalog. This Moxifloxacin Hydrochloride Eye Drops has been approved for marketing as a Class 4 chemical drug, marking that this product is considered to have passed the consistency evaluation of generic drugs

### Related Stocks

- [000650.CN](https://longbridge.com/en/quote/000650.CN.md)

## Related News & Research

- [Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners](https://longbridge.com/en/news/296910145.md)
- [Endovia Health opens FDA INAD file for CannEpil veterinary program](https://longbridge.com/en/news/296915045.md)
- [A: Q3 results exceeded expectations with strong growth in pharma, CDMO, and China, driving raised FY26 guidance](https://longbridge.com/en/news/297095880.md)
- [Qlife enters fully funded feasibility deal with global pharma company for Egoo Health biomarker application](https://longbridge.com/en/news/296995766.md)
- [Filament Health ships psilocybin candidate PEX010 for University of Washington Phase 2a cancer anxiety, depression trial](https://longbridge.com/en/news/296906129.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**